Neurophage, Inc. Raises $6.4 Million In Additional Financing

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Antitope Ltd., Announces Protein Deimmunisation Research Agreement with NeuroPhage Pharmaceuticals, Inc.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NeuroPhage Reports Beneficial Effects in Pre-clinical Parkinson’s Disease Model

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NeuroPhage extends Series B to $21.4M

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NeuroPhage Receives Michael J. Fox Foundation Funding

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NeuroPhage Selected as Top 10 CNS Biotech Company

© Neurophage Pharmaceuticals 2012